[go: up one dir, main page]

NO995928L - Alfa-1-antitrypsin-preparater samt fremgangsmåte ved fremstilling derav - Google Patents

Alfa-1-antitrypsin-preparater samt fremgangsmåte ved fremstilling derav

Info

Publication number
NO995928L
NO995928L NO995928A NO995928A NO995928L NO 995928 L NO995928 L NO 995928L NO 995928 A NO995928 A NO 995928A NO 995928 A NO995928 A NO 995928A NO 995928 L NO995928 L NO 995928L
Authority
NO
Norway
Prior art keywords
preparation
antitrypsin
preparations
alpha
inactive
Prior art date
Application number
NO995928A
Other languages
English (en)
Other versions
NO995928D0 (no
Inventor
Erwin Mattes
Peter H Matthiessen
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Ag filed Critical Baxter Ag
Publication of NO995928D0 publication Critical patent/NO995928D0/no
Publication of NO995928L publication Critical patent/NO995928L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C07K14/8125—Alpha-1-antitrypsin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det er beskrevet et naturlig, kromatografisk ren- set al-AT-preparat som har en renhet på minst 0,7 PE/mg protein og en relativ plasma-al-AT-aktivitet på minst 120 %. Forholdet mellom aktivt og inak- tivt al-AT er større enn i plasma. Dessuten er det beskrevet en fremgangsmåte ved fremstilling av dette preparat samt anvendelsen av et bærermateriale, f.eks. et uorgangisk basrermate- riale, såsom hydroksyapatitt, for å skille aktivt al-AT fra inaktivt al-AT.
NO995928A 1997-06-10 1999-12-03 Alfa-1-antitrypsin-preparater samt fremgangsmåte ved fremstilling derav NO995928L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0100797A AT407114B (de) 1997-06-10 1997-06-10 Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung
PCT/AT1998/000130 WO1998056821A1 (de) 1997-06-10 1998-05-20 Alpha 1-antitrypsin-präparation sowie verfahren zu deren herstellung

Publications (2)

Publication Number Publication Date
NO995928D0 NO995928D0 (no) 1999-12-03
NO995928L true NO995928L (no) 2000-02-09

Family

ID=3504791

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995928A NO995928L (no) 1997-06-10 1999-12-03 Alfa-1-antitrypsin-preparater samt fremgangsmåte ved fremstilling derav

Country Status (15)

Country Link
US (1) US6974792B2 (no)
EP (1) EP0991666B1 (no)
JP (1) JP2002510294A (no)
AT (1) AT407114B (no)
AU (1) AU729389B2 (no)
BR (1) BR9810002A (no)
CA (1) CA2293806C (no)
DE (1) DE59814132D1 (no)
DK (1) DK0991666T3 (no)
ES (1) ES2296334T3 (no)
HU (1) HUP0003712A1 (no)
NO (1) NO995928L (no)
PT (1) PT991666E (no)
SK (1) SK171699A3 (no)
WO (1) WO1998056821A1 (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3731400A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Methods and compositions useful in inhibiting apoptosis
AU2012203030B2 (en) * 2002-12-31 2015-02-19 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
US7777006B2 (en) 2002-12-31 2010-08-17 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
AU2015200572B2 (en) * 2002-12-31 2016-06-02 Csl Behring L.L.C. Method for purification of alpha-1-antitrypsin
CN1867582B (zh) * 2003-08-12 2010-06-16 奥克塔法马股份有限公司 制备α-1-抗胰蛋白酶溶液的方法
ES2622522T3 (es) 2003-08-26 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad proteasa de serina y su uso en métodos y composiciones para el tratamiento de infecciones bacterianas
SI1664123T2 (sl) * 2003-09-22 2012-03-30 Kamada Ltd Priprava inhibitorja alfa proteinaze v velikem merilu in njegova uporaba
GB0524432D0 (en) * 2005-11-30 2006-01-11 Nhs Blood & Transplant Method
PT1999262E (pt) * 2006-03-30 2012-10-11 Baxter Int Processo para a purificação de alfa 1-antitripsina recombinante envolvendo um passo de cromatografia de permuta aniónica.
EP2066174B1 (en) 2006-09-12 2017-11-08 Beth Israel Deaconess Medical Center, Inc. Compositions containing alpha-1-antitrypsin and methods for use
CN103396479A (zh) 2007-08-17 2013-11-20 Csl百灵有限公司 α-1-抗胰蛋白酶和载脂蛋白A-I的纯化方法
US20110002909A1 (en) * 2007-11-02 2011-01-06 Vikram Arora Method, composition, and article of manufacture for providing alpha-1 antitrypsin
NZ599783A (en) 2009-11-03 2013-10-25 Grifols Therapeutics Inc Composition and use for alpha-1 proteinase inhibitor
ES2648249T3 (es) 2009-11-24 2017-12-29 Grifols Therapeutics Inc. Procedimientos, composiciones y kits de liofilización
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
US10233556B2 (en) 2010-07-02 2019-03-19 Lam Research Corporation Dynamic modulation of cross flow manifold during electroplating
US10094034B2 (en) 2015-08-28 2018-10-09 Lam Research Corporation Edge flow element for electroplating apparatus
MX351189B (es) 2011-12-30 2017-10-04 Grifols Sa Inhibidor de alfa1-proteinasa para demorar el comienzo o progresión de exacerbaciones pulmonares.
CN103788209B (zh) * 2012-10-29 2016-02-24 广东双林生物制药有限公司 一种α1-蛋白酶抑制剂的制备方法
ES2799153T3 (es) 2013-03-29 2020-12-15 Univ Colorado Regents Alfa 1 antitripsina para uso en la preparación de un sujeto para trasplante
US10364505B2 (en) 2016-05-24 2019-07-30 Lam Research Corporation Dynamic modulation of cross flow manifold during elecroplating

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4439358A (en) * 1982-06-17 1984-03-27 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4697003A (en) * 1985-11-01 1987-09-29 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US6284874B1 (en) * 1994-06-17 2001-09-04 Alpha Therapeutic Corporation Process for separating α1-proteinase inhibitor from cohn fraction IV1 and IV4 paste
US5610285A (en) * 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US5760179A (en) * 1996-06-10 1998-06-02 Desmos, Inc. Purification of soluble laminin 5

Also Published As

Publication number Publication date
AU7418098A (en) 1998-12-30
EP0991666B1 (de) 2007-11-28
NO995928D0 (no) 1999-12-03
ES2296334T3 (es) 2008-04-16
WO1998056821A1 (de) 1998-12-17
CA2293806C (en) 2010-02-09
JP2002510294A (ja) 2002-04-02
PT991666E (pt) 2007-12-27
ATA100797A (de) 2000-05-15
US20020082214A1 (en) 2002-06-27
CA2293806A1 (en) 1998-12-17
EP0991666A1 (de) 2000-04-12
SK171699A3 (en) 2000-06-12
HUP0003712A1 (hu) 2001-02-28
DE59814132D1 (de) 2008-01-10
BR9810002A (pt) 2000-08-01
AT407114B (de) 2000-12-27
US6974792B2 (en) 2005-12-13
DK0991666T3 (da) 2008-04-14
AU729389B2 (en) 2001-02-01

Similar Documents

Publication Publication Date Title
NO995928L (no) Alfa-1-antitrypsin-preparater samt fremgangsmåte ved fremstilling derav
NO954342L (no) Erytropoietinanalogblandinger, samt fremgangsmåter ved fremstilling derav
AU5242000A (en) Nematicidal trifluorobutenes
MX9702865A (es) Agentes estrogenicos.
NO20061455L (no) 2,6 dioksopiperidin samt farmasoytiske preparater som inneholder disse
AU1750097A (en) Highly concentrated, lyophilized, and liquid factor ix formulations
MY116535A (en) New stable pharmaceutical preparation for producing propellant gas-free aerosols
JO2034B1 (en) Isotopes of the hormone peptide its uses and the chemical compounds it contains
CA2264901A1 (fr) Association inhibiteurs de no synthase et piegeurs des formes reactives de l'oxygene
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
CA2161881A1 (en) High lysine derivatives of alpha-hordothionin
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
TR200200785T2 (tr) 8-Fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-on türevleri
GB0011203D0 (en) Chemical compounds
IL114294A0 (en) Sterol derivatives
BG101892A (en) Sugar-modified cytostatics
ITFI920078A0 (it) Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umana.
NZ319138A (en) Composition containing cytochrome complex III and fenazaquin for combatting parasitic fungi
AU6633596A (en) Improved therapeutic agents
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
AU6415994A (en) Substituted caprolactams and derivatives thereof useful for treatment of hiv disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application